B cell immunotherapy in autoimmunity - 2010 update

Molecular Immunology

Volumn 48, Issue 11, 2011, Pages 1344-1347

  Chan, Andrew C ^a  

^a GENENTECH INC   (United States)

Author keywords

Autoantibodies; Autoimmunity; B cell immunodepletion; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus; Type 1 diabetes mellitus

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; BELIMUMAB; CD20 ANTIBODY; PLACEBO; RITUXIMAB;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOID CELL; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

MUS;

EID: 79956330472     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2010.11.021     Document Type: Review

References (35)

1. Amagai M., Hashimoto T., Shimizu N., Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J. Clin. Invest. 1994, 94:59-67.
2. Baker K.P., Edwards B.M., Main S.H., Choi G.H., Wager R.E., Halpern W.G., Lappin P.B., Riccobene T., Abramian D., Sekut L., Sturm B., Poortman C., Minter R.R., Dobson C.L., Williams E., Carmen S., Smith R., Roschke V., Hilbert D.M., Vaughan T.J., Albert V.R. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003, 48:3253-3265.
3. Barone F., Bombardieri M., Manzo A., Blades M.C., Morgan P.R., Challacombe S.J., Valesini G., Pitzalis C. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren's syndrome. Arthritis Rheum. 2005, 52:1773-1784.
4. Bradl M., Lassmann H. Progressive multiple sclerosis. Semin. Immunopathol. 2009, 31:455-465.
5. Cambridge G., Stohl W., Leandro M.J., Migone T.S., Hilbert D.M., Edwards J.C. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006, 54:723-732.
6. Daridon C., Burmester G.R., Dorner T. Anticytokine therapy impacting on B cells in autoimmune diseases. Curr. Opin. Rheumatol. 2009, 21:205-210.
7. Ding X., Diaz L.A., Fairley J.A., Giudice G.J., Liu Z. The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic. J. Invest. Dermatol. 1999, 112:739-743.
8. Donath J., Landsteiner K. Uber paroxysmale Haemoglobinurie. Munchen. Med. Wochen. 1904, 51:1590-1593.
9. Drachman D.B., Angus C.W., Adams R.N., Michelson J.D., Hoffman G.J. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N. Engl. J. Med. 1978, 298:1116-1122.
10. Furie R.A., Petri M.A., Wallace D.J., Ginzler E.M., Merrill J.T., Stohl W., Chatham W.W., Strand V., Weinstein A., Chevrier M.R., Zhong Z.J., Freimuth W.W. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009, 61:1143-1151.
11. George-Chandy A., Trysberg E., Eriksson K. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res. Ther. 2008, 10:R97.
12. Golovkina T.V., Shlomchik M., Hannum L., Chervonsky A. Organogenic role of B lymphocytes in mucosal immunity. Science 1999, 286:1965-1968.
13. Gong Q., Ou Q., Ye S., Lee W.P., Cornelius J., Diehl L., Lin W.Y., Hu Z., Lu Y., Chen Y., Wu Y., Meng Y.G., Gribling P., Lin Z., Nguyen K., Tran T., Zhang Y., Rosen H., Martin F., Chan A.C. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 2005, 174:817-826.
14. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., Tschopp J., Cachero T.G., Batten M., Wheway J., Mauri D., Cavill D., Gordon T.P., Mackay C.R., Mackay F. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J. Clin. Invest. 2002, 109:59-68.
15. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., Xu W., Parrish-Novak J., Foster D., Lofton-Day C., Moore M., Littau A., Grossman A., Haugen H., Foley K., Blumberg H., Harrison K., Kindsvogel W., Clegg C.H. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000, 404:995-999.
16. Hamaguchi Y., Uchida J., Cain D.W., Venturi G.M., Poe J.C., Haas K.M., Tedder T.F. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J. Immunol. 2005, 174:4389-4399.
17. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688.
18. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 2001, 7:365-368.
19. Hu C.Y., Rodriguez-Pinto D., Du W., Ahuja A., Henegariu O., Wong F.S., Shlomchik M.J., Wen L. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 2007, 117:3857-3867.
20. Humby F., Bombardieri M., Manzo A., Kelly S., Blades M.C., Kirkham B., Spencer J., Pitzalis C. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med. 2009, 6:e1.
21. Kayagaki N., Yan M., Seshasayee D., Wang H., Lee W., French D.M., Grewal I.S., Cochran A.G., Gordon N.C., Yin J., Starovasnik M.A., Dixit V.M. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002, 17:515-524.
22. Khan W.N. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J. Immunol. 2009, 183:3561-3567.
23. Lesley R., Xu Y., Kalled S.L., Hess D.M., Schwab S.R., Shu H.B., Cyster J.G. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004, 20:441-453.
24. McCarthy D.D., Summers-Deluca L., Vu F., Chiu S., Gao Y., Gommerman J.L. The lymphotoxin pathway: beyond lymph node development. Immunol. Res. 2006, 35:41-54.
25. Ngo V.N., Cornall R.J., Cyster J.G. Splenic T zone development is B cell dependent. J. Exp. Med. 2001, 194:1649-1660.
26. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., Gottlieb P.A., Marks J.B., McGee P.F., Moran A.M., Raskin P., Rodriguez H., Schatz D.A., Wherrett D., Wilson D.M., Lachin J.M., Skyler J.S. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 2009, 361:2143-2152.
27. Peterson K.S., Huang J.F., Zhu J., D'Agati V., Liu X., Miller N., Erlander M.G., Jackson M.R., Winchester R.J. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J. Clin. Invest. 2004, 113:1722-1733.
28. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004, 14:164-174.
29. Serreze D.V., Fleming S.A., Chapman H.D., Richard S.D., Leiter E.H., Tisch R.M. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J. Immunol. 1998, 161:3912-3918.
30. Signore A., Pozzilli P., Gale E.A., Andreani D., Beverley P.C. The natural history of lymphocyte subsets infiltrating the pancreas of NOD mice. Diabetologia 1989, 32:282-289.
31. Tew G.W., Rabbee N., Wolslegel K., Hsieh H.J., Monroe J.G., Behrens T.W., Brunetta P.G., Keir M.E. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus 2010, 19:146-157.
32. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., Brink R. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
33. Townsend M.J., Monroe J.G., Chan A.C. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol. Rev. 2010, 237:264-283.
34. Weyand C.M., Kang Y.M., Kurtin P.J., Goronzy J.J. The power of the third dimension: tissue architecture and autoimmunity in rheumatoid arthritis. Curr. Opin. Rheumatol. 2003, 15:259-266.
35. Xiu Y., Wong C.P., Bouaziz J.D., Hamaguchi Y., Wang Y., Pop S.M., Tisch R.M., Tedder T.F. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J. Immunol. 2008, 180:2863-2875.